


**Amendments to the Drawings:**

Please substitute the attached 16 sheets (Figs. 1A, 1B, 1C, 1D, 2, 3, 4A, 4B, 5, 6A, 6B, 7A, 7B, 7C, 7D, 8A, 8B, 8C, 8D, 9A, 9B, 10A, 10B, 10C, 11A, and 11B) of formal drawings for the informal drawings originally filed with the application. A separate Transmittal of Formal Drawings is submitted.


The drawing sheets attached in connection with the above-identified application containing Figures 1A, 1B, 1C, 1D, 2, 3, 4A, 4B, 5, 6A, 6B, 7A, 7B, 7C, 7D, 8A, 8B, 8C, 8D, 9A, 9B, 10A, 10B, 10C, 11A, and 11B are being presented as new formal drawing sheets to be substituted for the originally submitted drawing sheets from the application as filed in parent application Serial No. 09/476,484. The drawing Figures 4A, 5A, 9A, 9b, 11A, 11B, 11C, 11D and 12B have been deleted. Figure 4B has been renumbered as Figures 4A and B; Figure 5B has been renumbered as Figure 5; Figures 10A and 10B have been renumbered as Figures 9A and 9B; Figures 12A, 12C and 12D have respectively been renumbered as Figures 10A, 10B and 10C; and Figures 13A and 13B have been renumbered as Figures 11A and 11B. Appended to this amendment is an annotated copy of the original drawing sheets which have been marked to show changes presented in the replacement sheets of the drawings.

The changes described above which have been made to the Figures were made to overcome the rejections of the Draftsperson as stated on the PTO 948 dated March 25, 2000, in parent application Serial No. 09/476,484. Figures 4A, 5A, 9A, 9b, 11A, 11B, 11C, 11D and 12B are being canceled solely because the original micrographs have been misplaced and the quality of the micrograph copies that are available to Applicants was not acceptable to the Draftsperson. The material that was disclosed in original Figures 4A, 5A, 9A, 9b, 11A, 11B, 11C, 11D and 12B is adequately disclosed in the specification. *See, e.g.,* the Brief Description of the Figures section beginning on page 21 and the Examples section beginning on page 45. Figures 4A, 5A, 9A, 9b, 11A, 11B, 11C, 11D and 12B are being canceled without prejudice or disclaimer of the subject matter contained therein.

FIG. 1A



**FIG. 1B**



**FIG. 1C**







FIG. 2



**FIG. 3**



INFILTRATIVE CELL NUMBER  
IN THE AIR POUCH ( $\times 10^6$ )




FIG. 4A

MACROPHAGE RATIO IN  
INFILTRATIVE CELLS (%)






FIG. 4B

FIG. 5




**FIG. 6a**

Phosphorylation of Pyk2  
in P388D1 Cells after  
LPS Stimulation



IP anti Pyk2  
Blot anti pTyr

**FIG. 6b**



IP anti Pyk2  
Blot anti pTyr

Expression of Pyk2 w.t.-HA and Pyk2-ATP-HA in P388D.1 cells  
is inducible via Doxycyclin Utilizing the Tet-On Gene Expression System

**FIG. 7b**

Pyk2-ATP-HA With Doxycyclin  
Clone #    3    4    5    6    7    8    1

Pyk2 w.t.-HA  
With Doxycyclin  
25      31



**FIG. 7a**

Pyk2-ATP-HA Without Doxycyclin


**FIG. 7d**




Blot anti-HA

Expression of Pyk2 Kinase Mutant Suppresses  
TNF Secretion in P388D1 Cells


**FIG. 8a**



**FIG. 8b**



**FIG. 8c**



**FIG. 8d**







FIG. 9A



**FIG. 9B**



## FIG. 10A



Blot: anti-rhoA

FIG. 10B




FIG. 10C





FIG. 11A



**FIG. 11B**

